Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase... von Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V., Muro, Kei, Fuchs, Charles S., Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I., Borg, Christophe, Doi, Toshihiko, Yoon, Harry H., Savage, Mary J., Wang, Jiangdian, Dalal, Rita P., Shah, Sukrut, Wainberg, Zev A., Chung, Hyun Cheol

Volltext

Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer von Liu, Xiangsheng, Jiang, Jinhong, Chan, Ryan, Ji, Ying, Lu, Jianqin, Liao, Yu-Pei, Okene, Michael, Lin, Joshua, Lin, Paulina, Chang, Chong Hyun, Wang, Xiang, Tang, Ivanna, Zheng, Emily, Qiu, Waveley, Wainberg, Zev A, Nel, Andre E, Meng, Huan

Volltext

Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer von Court, Colin M., Ankeny, Jacob S., Sho, Shonan, Winograd, Paul, Hou, Shuang, Song, Min, Wainberg, Zev A., Girgis, Mark D., Graeber, Thomas G., Agopian, Vatche G., Tseng, Hsian-Rong, Tomlinson, James S.

Volltext

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial von Wainberg, Zev A., Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian A., Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Zahlten-Kümeli, Anita, Taylor, Kate, Enzinger, Peter C.

Volltext

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer von Shah, Manish A, Wainberg, Zev A, Catenacci, Daniel V T, Hochster, Howard S, Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C, Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P

Volltext

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors von Gelderblom, Hans, Wagner, Andrew J., Tap, William D., Palmerini, Emanuela, Wainberg, Zev A., Desai, Jayesh, Healey, John H., Sande, Michiel A. J., Bernthal, Nicholas M., Staals, Eric L., Peterfy, Charles G., Frezza, Anna Maria, Hsu, Henry H., Wang, Qiang, Shuster, Dale E., Stacchiotti, Silvia

Volltext

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance von Tanaka, Hiroshi, Kono, Evelyn, Tran, Chau P, Miyazaki, Hideyo, Yamashiro, Joyce, Shimomura, Tatsuya, Fazli, Ladan, Wada, Robert, Huang, Jiaoti, Vessella, Robert L, An, Jaibin, Horvath, Steven, Gleave, Martin, Rettig, Matthew B, Wainberg, Zev A, Reiter, Robert E

Volltext

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor von Bendell, Johanna C, Javle, Milind, Bekaii-Saab, Tanios S, Finn, Richard S, Wainberg, Zev A, Laheru, Daniel A, Weekes, Colin D, Tan, Benjamin R, Khan, Gazala N, Zalupski, Mark M, Infante, Jeffrey R, Jones, Suzanne, Papadopoulos, Kyriakos P, Tolcher, Anthony W, Chavira, Renae E, Christy-Bittel, Janna L, Barrett, Emma, Patnaik, Amita

Volltext

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1 von Liu, Xiangsheng, Jiang, Jinhong, Liao, Yu‐Pei, Tang, Ivanna, Zheng, Emily, Qiu, Waveley, Lin, Matthew, Wang, Xiang, Ji, Ying, Mei, Kuo‐Ching, Liu, Qi, Chang, Chong Hyun, Wainberg, Zev A., Nel, Andre E., Meng, Huan

Volltext

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabi... von Wainberg, Zev A, Feeney, Kynan, Lee, Myung Ah, Muñoz, Andrés, Gracián, Antonio Cubillo, Lonardi, Sara, Ryoo, Baek-Yeol, Hung, Annie, Lin, Yong, Bendell, Johanna, Hecht, J Randolph

Volltext

Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 von Van Cutsem, Eric, Amonkar, Mayur, Fuchs, Charles S., Alsina, Maria, Özgüroğlu, Mustafa, Bang, Yung-Jue, Chung, Hyun Cheol, Muro, Kei, Goekkurt, Eray, Benson, Al B., Sun, Weijing, Wainberg, Zev A., Norquist, Josephine M., Chen, Xinqun, Shih, Chie-Schin, Shitara, Kohei

Volltext

Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin‐18 isoform 2 splicing variants in gastric cancer and other solid tumours von Katoh, Masuko, Nakayama, Izuma, Wainberg, Zev A, Shitara, Kohei, Katoh, Masaru

Volltext

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer von Shah, Manish A., Wainberg, Zev A., Catenacci, Daniel V. T., Hochster, Howard S., Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C., Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P.

Volltext

Impact of Tumor Grade on Pancreatic Cancer Prognosis: Validation of a Novel TNMG Staging System von Rochefort, Matthew M., Ankeny, Jacob S., Kadera, Brian E., Donald, Graham W., Isacoff, William, Wainberg, Zev A., Hines, O. Joe, Donahue, Timothy R., Reber, Howard A., Tomlinson, James S.

Volltext

Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option von Park, Haeseong, Klempner, Samuel J, Chao, Joseph, Wainberg, Zev A, Lukanowski, Mariusz, Chenji, Suresh, Bourke, Shannon, Chatterjee, Anindya, Lorenzen, Sylvie

Volltext

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer von Shah, Manish A, Wainberg, Zev A, Catenacci, Daniel V T, Hochster, Howard S, Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C, Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P

Volltext

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions von Katoh, Masuko, Loriot, Yohann, Brandi, Giovanni, Tavolari, Simona, Wainberg, Zev A., Katoh, Masaru

Volltext

Safety Considerations of Cancer Nanomedicine—A Key Step toward Translation von Liu, Xiangsheng, Tang, Ivanna, Wainberg, Zev A., Meng, Huan

Volltext

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC) von Hecht, J. Randolph, Papadopoulos, Kyriakos P., Falchook, Gerald S., Patel, Manish R., Infante, Jeffrey R., Aljumaily, Raid, Wong, Deborah J., Autio, Karen A., Wainberg, Zev A., Bauer, Todd M., Javle, Milind, Pant, Shubham, Bendell, Johanna, Hung, Annie, Ratti, Navneet, VanVlasselaer, Peter, Verma, Rakesh, Leveque, Joseph, Rao, Sujata, Oft, Martin, Naing, Aung

Volltext

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial von Subbiah, Vivek, Lassen, Ulrik, Élez, Elena, Italiano, Antoine, Curigliano, Giuseppe, Javle, Milind, de Braud, Filippo, Prager, Gerald W, Greil, Richard, Stein, Alexander, Fasolo, Angelica, Schellens, Jan H M, Wen, Patrick Y, Viele, Kert, Boran, Aislyn D, Gasal, Eduard, Burgess, Paul, Ilankumaran, Palanichamy, Wainberg, Zev A

Volltext